Co-Authors
This is a "connection" page, showing publications co-authored by PATRICK HWU and SATTVA S NEELAPU.
Connection Strength
0.623
-
Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. Nat Rev Clin Oncol. 2018 04; 15(4):218.
Score: 0.155
-
Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018 Jan; 15(1):47-62.
Score: 0.151
-
Author Correction: Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nat Commun. 2024 Jul 04; 15(1):5621.
Score: 0.061
-
Correction: IL-1a Mediates Innate and Acquired Resistance to Immunotherapy in Melanoma. J Immunol. 2024 Feb 01; 212(3):500.
Score: 0.059
-
Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nat Commun. 2022 04 12; 13(1):1970.
Score: 0.052
-
IL-1a Mediates Innate and Acquired Resistance to Immunotherapy in Melanoma. J Immunol. 2021 04 15; 206(8):1966-1975.
Score: 0.048
-
Bypassing STAT3-mediated inhibition of the transcriptional regulator ID2 improves the antitumor efficacy of dendritic cells. Sci Signal. 2016 09 27; 9(447):ra94.
Score: 0.035
-
Induction of TLR4-dependent CD8+ T cell immunity by murine ?-defensin2 fusion protein vaccines. Vaccine. 2011 Apr 18; 29(18):3476-82.
Score: 0.024
-
A novel strategy for rapid and efficient isolation of human tumor-specific CD4(+) and CD8(+) T-cell clones. J Immunol Methods. 2008 Feb 29; 331(1-2):13-26.
Score: 0.019
-
Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and lymphoma mouse models. Vaccine. 2007 Nov 14; 25(46):7955-61.
Score: 0.019